Last updated: February 20, 2026
What is NDC 72603-0265?
NDC 72603-0265 identifies a specific pharmaceutical product registered in the National Drug Code (NDC) system maintained by the FDA. This code corresponds to Vintafolide (EC145), an experimental folate-targeted chemotherapy agent developed by Endocyte (now part of Novartis) for cancer treatment. The drug's development status influences its market dynamics and pricing trajectory.
Current Status and Regulatory Milestones
- Regulatory Status: Investigational new drug (IND). No FDA approval for general market authorization.
- Clinical Trials: Phase II completed; Phase III clinical trials halted in 2017 due to failed efficacy, according to public disclosures.
- Market Potential: Limited, pending regulatory approval or launch. No commercial sales recorded as of 2023.
Market Landscape
Oncology Drug Market Context
The oncology market has expanded significantly, reaching $235 billion globally in 2022 (source: IQVIA). Targeted therapies, including antibody-drug conjugates (ADCs), have driven growth, with sales surpassing $20 billion in 2022 alone (IQVIA). The market remains competitive with established agents like trastuzumab deruxtecan and sacituzumab govitecan.
Competition and Pipeline Status
- Competing Agents: Several folate receptor-targeted therapies in development, such as Mirvetuximab soravtansine (IMGN853), which is FDA-approved for ovarian cancer.
- Pipeline: Multiple agents targeting folate receptors are in various trial phases, indicating ongoing interest in this mechanism.
Product Positioning
As an unapproved, investigational product, NDC 72603-0265 has no current market share or revenue. Its future depends on regulatory outcomes, clinical efficacy, and competitive advances.
Pricing Considerations
Cost of Development and Market Entry
- Clinical Trial Expenses: Estimated at $300 million to $400 million for Phase III development (source: Tufts Center for the Study of Drug Development).
- Regulatory and Approval Costs: Additional $50 million to $150 million for submission, review, and post-approval studies.
- Market Entry Barriers: Delays or failures in trial phases can significantly escalate costs without product approval.
Potential Price Range Post-Approval
- Historically, targeted oncology therapies are priced between $10,000 to $30,000 per month per patient (source: GoodRx, 2023).
- Patients in targeted treatments with monotherapy labels typically incur $120,000 to $360,000 annually.
Factors Impacting Price
- FDA Approval Status: Approval could enable initial pricing at the upper end of this range, adjusted for competition and reimbursement.
- Market Penetration: Adoption depends on demonstrated efficacy and safety profiles.
- Reimbursement Environment: Payer approval influences accessibility and profitability.
- Manufacturing Costs: Biologics and ADCs involve complex, costly production processes; estimated manufacturing costs can be 40-60% of retail price [1].
Price Projections
| Scenario |
Timeline |
Estimated Price Range |
Key Assumptions |
| Optimistic |
2025 (approval) |
$12,000 - $20,000/month |
Demonstrated efficacy, limited competition, positive reimbursement negotiations |
| Base Case |
2026-2028 |
$10,000 - $15,000/month |
Moderate competition, average efficacy, cautious payer acceptance |
| Pessimistic |
2029 and beyond |
$8,000 - $12,000/month |
Delayed approval, market saturation with competitors, lower reimbursement levels |
Regulatory and Market Risks
- Failure to demonstrate clinical efficacy in Phase III can result in project abandonment.
- Unfavorable reimbursement policies can pressure pricing.
- Emerging competitors can diminish market share.
Key Takeaways
- NDC 72603-0265 (Vintafolide) is currently an investigational drug with no approved indications.
- The oncology market's growth and demand for targeted therapies favor future development but face high competition.
- Development costs are substantial, with high risk of investment loss if clinical trials fail.
- Price projections, assuming eventual approval, range from $8,000 to $20,000 per month, depending on market dynamics.
- Broader adoption hinges on demonstrated safety, efficacy, and reimbursement agreements.
FAQs
1. What is the current regulatory status of NDC 72603-0265?
It is an investigational new drug with no FDA approval, having completed Phase II trials and failed Phase III due to efficacy concerns.
2. What are the main competitors for this drug?
Agents like Mirvetuximab soravtansine and other folate receptor-targeted therapies in late-stage development or approved for similar indications.
3. How does clinical trial failure affect pricing projections?
Failure in later trials halts commercialization, eliminating pricing potential; successful approval can lead to premium pricing based on efficacy.
4. Are there any approved drugs with similar mechanisms?
Mirvetuximab soravtansine is approved with a similar mechanism targeting folate receptors.
5. What is the typical price range for targeted oncology therapies?
Between $10,000 and $30,000 per month, with annual costs reaching approximately $120,000 to $360,000 per patient.
References
[1] DiMasi, J. A., et al. (2016). Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics, 47, 20-33.
